Home / Themes / Biotech '26: AI Driven Drug Discovery
Biotech '26: AI Driven Drug Discovery
Last updated
Theme no thesis · 1/5 sections · Tickers 7 with notes · 7 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Upcoming Catalysts
| Catalyst | Estimated Timing | Estimated Date Start | Estimated Date End | Why It Matters | Ticker Or Theme Specific | Source Types | Contributing Tickers | Mention Count | Bridge Mention Count | Base Score | Theme Base Score | Source Weight | Specificity Weight | Macro Bridge | Macro Bridge Multiplier | Theme Importance Score | Theme Score | Manual Override | Date Aggregated | Catalyst Source | Catalyst ID | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICON's ability to sustain positive trends in RFP flow and gross business awards throughout 2026 is a key indicator. | sustain the positive trends of the last 2 quarters regarding RFP flow and gross bookings... in 2026 | 2026-01-01 | 2026-12-31 | Sustained strong demand indicators are vital for future revenue growth and investor confidence, signaling a healthier market environment for ICON and the broader CRO sector. | Theme | earnings_transcript | ICLR | 2 | 2 | 0.0003 | 0.2019 | 1.25 | 0.92 | Regulatory/Policy | 1.35 | 31.3492 | 0.0421 | False | 2026-03-16 | Theme aggregation | |||
| Rapid Micro Biosystems aims to realize meaningful consumable cost reductions and achieve positive consumable gross margins, leading to overall gross margin expansion. | starting in the first half and accelerating in the second half of 2026 | 2026-01-01 | 2026-12-31 | Successful implementation of cost reductions will directly improve profitability and gross margins, which is a key strategic priority and could significantly impact financial results and investor confidence. This aligns with the broader theme of operational efficiency in biotech. | Theme | earnings_transcript | RPID | 2 | 2 | 0.0 | 0.2 | 1.25 | 0.92 | Regulatory/Policy | 1.35 | 31.0553 | 0.0007 | False | 2026-03-16 | Theme aggregation | |||
| ICON's ability to improve its win rate in the biotech sector and convert elevated RFP flow into higher gross bookings is a key objective. | work to do for ICON there | 2026-01-01 | 2026-12-31 | Improving win rates in the growing biotech sector would significantly boost ICON's gross bookings and future revenue, enhancing market share and investor confidence, and reflecting the company's ability to capitalize on industry growth. | Theme | earnings_transcript | ICLR | 1 | 1 | 0.0003 | 0.0019 | 1.25 | 0.92 | Regulatory/Policy, Economic | 1.688 | 0.3739 | 0.0579 | False | 2026-03-16 | Theme aggregation | |||
| ICON aims to achieve a return to more normalized levels of study cancellations. | as we move into 2026, certainly over the course of the year | 2026-01-01 | 2026-12-31 | A moderation in elevated cancellation rates would positively impact ICON's net book-to-bill, improve backlog quality, and support future revenue growth, which is crucial for investor sentiment and overall market stability in clinical research. | Theme | earnings_transcript | ICLR | 1 | 1 | 0.0003 | 0.0019 | 1.25 | 0.92 | Economic | 1.25 | 0.277 | 0.0364 | False | 2026-03-16 | Theme aggregation | |||
| ICON's success in optimizing the burn rate of actively enrolling studies is a focus for 2026. | optimize the burn rate of studies that are actively enrolling in 2026 | 2026-01-01 | 2026-12-31 | An improved burn rate would accelerate revenue recognition from the existing backlog, positively impacting top-line growth and potentially enhancing margins, demonstrating efficient project management in clinical trials. | Ticker | earnings_transcript | ICLR | 1 | 1 | 0.0002 | 0.0016 | 1.25 | 0.92 | 1.0 | 0.1831 | 0.0219 | False | 2026-03-16 | Theme aggregation | ||||
| The actual impact of increased pass-through revenue mix and competitive pricing on ICON's gross and EBITDA margins in 2026 is a significant factor. | weigh on margin outlook for next year [2026] | 2026-01-01 | 2026-12-31 | These factors are expected to pressure profitability, and the degree to which ICON can mitigate them through cost management and technology will be key for investor sentiment and valuation, highlighting the importance of cost control in a competitive market. | Ticker | earnings_transcript | ICLR | 1 | 1 | 0.0002 | 0.0016 | 1.25 | 0.92 | 1.0 | 0.1831 | 0.0219 | False | 2026-03-16 | Theme aggregation | ||||
| ICON aims for the successful acceleration and deployment of AI-enabled technologies and external partnerships to enhance efficiency and capabilities. | accelerate investments in AI-enabled technologies and external partnerships | 2026-01-01 | 2027-12-31 | Successful deployment could lead to improved operational efficiency, reduced costs, and enhanced service offerings, potentially offsetting margin pressures and driving long-term value creation. This is directly aligned with the "Biotech '26: AI Driven Drug Discovery" theme. | Ticker | earnings_transcript | ICLR | 1 | 1 | 0.0002 | 0.0016 | 1.25 | 0.85 | 1.0 | 0.1691 | 0.0202 | False | 2026-03-16 | Theme aggregation | ||||
| Rapid Micro Biosystems is discussing and potentially securing new collaboration opportunities with Samsung Biologics beyond the current Growth Direct system deployment. | in the quarters and years ahead | 2026-04-01 | 2028-03-12 | Expanding the partnership with a major CDMO like Samsung Biologics could lead to new revenue streams, broader market penetration, and enhanced credibility, positively impacting long-term growth prospects and demonstrating strategic partnerships in the biotech industry. | Theme | earnings_transcript | RPID | 1 | 1 | 0.0 | 0.0 | 1.25 | 0.85 | Regulatory/Policy | 1.35 | 0.0049 | 0.0007 | False | 2026-03-16 | Theme aggregation | |||
| Rapid Micro Biosystems aims for the completion of at least 25 validations of Growth Direct systems in 2026, including those from large multisystem orders like Amgen and Samsung Biologics. | at least 25 validations in 2026 | 2026-01-01 | 2026-12-31 | Validations are critical for systems to become fully operational and start generating recurring consumable revenue. A faster validation pace can accelerate recurring revenue growth and improve service margins, indicating market adoption and revenue realization. | Ticker | earnings_transcript | RPID | 1 | 1 | 0.0 | 0.0 | 1.25 | 0.92 | 1.0 | 0.0033 | 0.0004 | False | 2026-03-16 | Theme aggregation | ||||
| MilliporeSigma's contribution to Rapid Micro Biosystems' system placements in 2026, and whether they satisfy their full year 2 system commitment, is a key focus. | 2026 system placements, with some potentially placed in Q1 2027 | 2026-01-01 | 2027-03-31 | The partnership is expected to meaningfully contribute to system placements and broaden global reach. The extent of this contribution will directly impact revenue and growth targets for 2026, demonstrating successful strategic alliances in the biotech space. | Ticker | earnings_transcript | RPID | 1 | 1 | 0.0 | 0.0 | 1.25 | 0.85 | 1.0 | 0.003 | 0.0004 | False | 2026-03-16 | Theme aggregation | ||||
| Completion of the acquisition of Ventix. | upcoming acquisition | 2026-02-04 | 2026-12-31 | This strategic action will add multiple clinical stage assets to Lilly's pipeline, potentially impacting future growth and investor sentiment. | Ticker | LLY (ticker) | LLY_f0ee4b85 | 2026-02-04 | earnings_transcript | ||||||||||||||
| FDA approval and US launch of Orforglipron for chronic weight management, expected in Q2 2026. | during 2026 | 2026-04-01 | 2026-06-30 | This launch is expected to expand the obesity market by reaching patients who prefer oral options, driving significant volume growth and potentially offsetting pricing headwinds. | Ticker | LLY (ticker) | LLY_3d4291a8 | 2026-02-04 | earnings_transcript | ||||||||||||||
| Anticipated reduction in Medicaid access for obesity coverage in key states like California. | in 2026 | 2026-01-01 | 2026-12-31 | This could negatively impact volume growth and access for a segment of patients, potentially acting as a drag on revenue. | Ticker | LLY (ticker) | LLY_e5f65ab8 | 2026-02-04 | earnings_transcript | ||||||||||||||
| Phase 3 readout of the 8,000-patient EMBER-4 trial for Imlunestrant in adjuvant breast cancer. | the next phase three readout | 2026-02-04 | 2026-12-31 | Positive data could establish Imlunestrant as a significant treatment option in early breast cancer, expanding its label and revenue potential for Lilly's oncology portfolio. | Ticker | LLY (ticker) | LLY_3bb3949c | 2026-02-04 | earnings_transcript | ||||||||||||||
| Initiation of new Phase 3 programs for two oncology small molecules: tirsolecimid and vepubratinib. | expect to initiate new phase three programs | 2026-02-04 | 2026-12-31 | This advances Lilly's oncology pipeline, potentially leading to new treatment options with improved tolerability and efficacy, supporting long-term growth. | Ticker | LLY (ticker) | LLY_13c4f6ae | 2026-02-04 | earnings_transcript | ||||||||||||||
| Initiation of several more Phase 2 and Phase 3 trials for brenepatide, including a Phase 3 trial for major depressive disorder. | in 2026 | 2026-02-04 | 2026-12-31 | Expands the potential applications of incretins into neuroscience, opening new large markets and diversifying Lilly's pipeline beyond cardiometabolic health. | Ticker | LLY (ticker) | LLY_41973547 | 2026-02-04 | earnings_transcript | ||||||||||||||
| Readout of six additional Phase 3 trials for Retatrutide, including the core registration package for TRIUMPH (obesity) and Transcend (type 2 diabetes) programs. | in 2026 | 2026-02-04 | 2026-12-31 | These readouts are crucial for the regulatory submission of Retatrutide, which has shown significant weight loss potential and could become a new treatment option for severe obesity and T2D. | Ticker | LLY (ticker) | LLY_9d9c78c8 | 2026-02-04 | earnings_transcript | ||||||||||||||
| Regulatory submission of the Core TRIUMPH program results for Retatrutide for overweight, obesity, obstructive sleep apnea, and osteoarthritis of the knee. | in 2026 | 2026-02-04 | 2026-12-31 | This submission initiates the regulatory process for Retatrutide across multiple indications, paving the way for future approvals and market entry, further strengthening Lilly's incretin portfolio. | Ticker | LLY (ticker) | LLY_93c0ffad | 2026-02-04 | earnings_transcript | ||||||||||||||
| Top-line results from the Together PSO trial evaluating Taltz and Zepbound in adults with moderate to severe plaque psoriasis and obesity/overweight. | in 2026 | 2026-02-04 | 2026-12-31 | Positive results could demonstrate additional efficacy of incretin combinations in immunology, expanding the utility and market for both Taltz and Zepbound. | Ticker | LLY (ticker) | LLY_2a06adb9 | 2026-02-04 | earnings_transcript | ||||||||||||||
| Gaining Mounjaro reimbursement in additional international countries for type 2 diabetes. | ongoing effort | 2026-02-04 | 2027-12-31 | Successful reimbursement efforts will expand access and drive volume growth for Mounjaro in international markets, contributing to OUS revenue. | Ticker | LLY (ticker) | LLY_5dfbe593 | 2026-02-04 | earnings_transcript | ||||||||||||||
| ICON's ability to achieve a return to more normalized levels of study cancellations. | as we move into 2026, certainly over the course of the year | 2026-01-01 | 2026-12-31 | A moderation in elevated cancellation rates would positively impact ICON's net book-to-bill, improve backlog quality, and support future revenue growth, which is crucial for investor sentiment. | Ticker | ICLR (ticker) | ICLR_157b8ebb | 2025-10-23 | earnings_transcript | ||||||||||||||
| ICON's ability to sustain positive trends in RFP flow and gross business awards throughout 2026. | sustain the positive trends of the last 2 quarters regarding RFP flow and gross bookings... in 2026 | 2026-01-01 | 2026-12-31 | Sustained strong demand indicators are vital for future revenue growth and investor confidence, signaling a healthier market environment for ICON. | Ticker | ICLR (ticker) | ICLR_ce25e1b7 | 2025-10-23 | earnings_transcript | ||||||||||||||
| ICON's success in optimizing the burn rate of actively enrolling studies. | optimize the burn rate of studies that are actively enrolling in 2026 | 2026-01-01 | 2026-12-31 | An improved burn rate would accelerate revenue recognition from the existing backlog, positively impacting top-line growth and potentially enhancing margins. | Ticker | ICLR (ticker) | ICLR_322ecde8 | 2025-10-23 | earnings_transcript | ||||||||||||||
| The actual impact of increased pass-through revenue mix and competitive pricing on ICON's gross and EBITDA margins in 2026. | weigh on margin outlook for next year [2026] | 2026-01-01 | 2026-12-31 | These factors are expected to pressure profitability, and the degree to which ICON can mitigate them through cost management and technology will be key for investor sentiment and valuation. | Ticker | ICLR (ticker) | ICLR_901b8734 | 2025-10-23 | earnings_transcript | ||||||||||||||
| Successful acceleration and deployment of AI-enabled technologies and external partnerships to enhance efficiency and capabilities. | accelerate investments in AI-enabled technologies and external partnerships | 2026-01-01 | 2027-12-31 | Successful deployment could lead to improved operational efficiency, reduced costs, and enhanced service offerings, potentially offsetting margin pressures and driving long-term value creation. | Ticker | ICLR (ticker) | ICLR_d1d7bdc6 | 2025-10-23 | earnings_transcript | ||||||||||||||
| ICON's ability to improve its win rate in the biotech sector and convert elevated RFP flow into higher gross bookings. | work to do for ICON there | 2026-01-01 | 2026-12-31 | Improving win rates in the growing biotech sector would significantly boost ICON's gross bookings and future revenue, enhancing market share and investor confidence. | Ticker | ICLR (ticker) | ICLR_9b920956 | 2025-10-23 | earnings_transcript | ||||||||||||||
| Outcome of Medpace's initiatives to expand its pipeline of opportunities and improve its win rate, and the resulting trend in cancellation rates and net new business awards. | over the next few quarters | 2026-04-01 | 2026-12-31 | High cancellation rates and weak gross bookings have led to a low book-to-bill ratio and raise concerns about future revenue growth. Success in these initiatives is critical to improving backlog and restoring a desired growth profile. | Ticker | MEDP (ticker) | MEDP_54a92808 | 2026-04-22 | earnings_transcript | ||||||||||||||
| Realization of management's expectation for pass-through revenues to decrease as a percentage of total revenue, driven by the winding down of some metabolic studies. | end the year lower than what we started this year at | 2026-04-22 | 2026-12-31 | A decrease in the proportion of pass-through revenues, which typically have lower margins, could positively impact the company's overall EBITDA margin and the quality of its revenue. | Ticker | MEDP (ticker) | MEDP_295080d7 | 2026-04-22 | earnings_transcript | ||||||||||||||
| Rapid Micro Biosystems realizing meaningful consumable cost reductions and achieving positive consumable gross margins, leading to overall gross margin expansion. | starting in the first half and accelerating in the second half of 2026 | 2026-01-01 | 2026-12-31 | Successful implementation of cost reductions will directly improve profitability and gross margins, which is a key strategic priority and could significantly impact financial results and investor confidence. | Ticker | RPID (ticker) | RPID_ef9efe6f | 2026-03-12 | earnings_transcript | ||||||||||||||
| MilliporeSigma's contribution to Rapid Micro Biosystems' system placements in 2026, and whether they satisfy their full year 2 system commitment. | 2026 system placements, with some potentially placed in Q1 2027 | 2026-01-01 | 2027-03-31 | The partnership is expected to meaningfully contribute to system placements and broaden global reach. The extent of this contribution will directly impact revenue and growth targets for 2026. | Ticker | RPID (ticker) | RPID_3ef2524b | 2026-03-12 | earnings_transcript | ||||||||||||||
| Completion of at least 25 validations of Growth Direct systems in 2026, including those from large multisystem orders like Amgen and Samsung Biologics. | at least 25 validations in 2026 | 2026-01-01 | 2026-12-31 | Validations are critical for systems to become fully operational and start generating recurring consumable revenue. A faster validation pace can accelerate recurring revenue growth and improve service margins. | Ticker | RPID (ticker) | RPID_20ea1368 | 2026-03-12 | earnings_transcript | ||||||||||||||
| Rapid Micro Biosystems discussing and potentially securing new collaboration opportunities with Samsung Biologics beyond the current Growth Direct system deployment. | in the quarters and years ahead | 2026-04-01 | 2028-03-12 | Expanding the partnership with a major CDMO like Samsung Biologics could lead to new revenue streams, broader market penetration, and enhanced credibility, positively impacting long-term growth prospects. | Ticker | RPID (ticker) | RPID_331042b0 | 2026-03-12 | earnings_transcript | ||||||||||||||
| Rapid Micro Biosystems is set to release its next-generation cloud-native software platform, leveraging AI-driven analytics and insights. | second half of 2026 | 2026-07-01 | 2026-12-31 | This new platform could redefine the Growth Direct experience, provide significant additional value to customers, and potentially open new avenues for high-margin recurring revenue, impacting long-term growth and valuation. This directly relates to the "AI Driven Drug Discovery" theme by enhancing data analytics and insights. | Theme | earnings_transcript | RPID | 1 | 1 | 0.0 | 0.0 | 1.25 | 0.92 | Regulatory/Policy | 1.35 | 0.0053 | 0.0007 | False | 2026-03-16 | Theme aggregation | |||
| New Medicare access to obesity medicines becomes effective. | no later than July 1, 2026 | 2026-07-01 | 2026-07-01 | This implementation is anticipated to drive substantial volume growth and market expansion by making obesity medicines more affordable for millions of Americans. | Ticker | LLY (ticker) | LLY_04a5f0cf | 2026-02-04 | earnings_transcript | ||||||||||||||
| Results from the Phase 3 pirtobrutinib trial, Bruin CLL322, evaluating pirtobrutinib in previously treated CLL/SLL patients. | Later this year | 2026-07-01 | 2026-12-31 | Successful results could form the basis for an additional regulatory submission later in the year, expanding the potential market for pirtobrutinib in oncology. | Ticker | LLY (ticker) | LLY_ab8f04c3 | 2026-02-04 | earnings_transcript | ||||||||||||||
| Completion of the US regulatory submission of Orforglipron for type 2 diabetes. | later this year after the Achieve IV trial is complete | 2026-07-01 | 2026-12-31 | This submission will expand the potential market for Orforglipron into type 2 diabetes, leveraging its oral formulation for broader patient access and revenue generation. | Ticker | LLY (ticker) | LLY_84cbeb5e | 2026-02-04 | earnings_transcript | ||||||||||||||
| Increased employer opt-in for commercial coverage of obesity medicines. | as we head into the back end of this year and mostly into 2027 | 2026-07-01 | 2027-12-31 | Expanded commercial coverage will increase access and reimbursement for obesity medicines, driving volume growth and revenue for the broader market. | Theme | LLY (ticker) | LLY_ada93b14 | 2026-02-04 | earnings_transcript | ||||||||||||||
| Medpace appoints a new President to succeed Jesse Geiger, who is departing. | not in the near term | 2026-07-01 | 2027-04-22 | The appointment of a new President is a key leadership transition that could influence strategic direction, operational execution, and investor confidence, despite management's assurance of a strong team. | Ticker | MEDP (ticker) | MEDP_f4e43f3e | 2026-04-22 | earnings_transcript | ||||||||||||||
| Release of Rapid Micro Biosystems' next-generation cloud-native software platform, leveraging AI-driven analytics and insights. | second half of 2026 | 2026-07-01 | 2026-12-31 | This new platform could redefine the Growth Direct experience, provide significant additional value to customers, and potentially open new avenues for high-margin recurring revenue, impacting long-term growth and valuation. | Ticker | RPID (ticker) | RPID_600f7b72 | 2026-03-12 | earnings_transcript | ||||||||||||||
| Launch of Orforglipron in a few international markets (e.g., UAE). | a few markets late in 2026 | 2026-10-01 | 2026-12-31 | This marks the beginning of the international rollout for oral Orforglipron, contributing to global revenue growth and market penetration. | Ticker | LLY (ticker) | LLY_cf82d1b5 | 2026-02-04 | earnings_transcript | ||||||||||||||
| Medpace achieving net financial benefits from its investments in Artificial Intelligence (AI) initiatives. | a few years out | 2028-01-01 | 2029-12-31 | While AI is a significant industry trend, management expects that investments in AI will outweigh efficiency gains for at least the next two years, impacting the timeline for any positive financial contribution from AI. | Ticker | MEDP (ticker) | MEDP_e1f9490e | 2026-04-22 | earnings_transcript |
Constituents
- — Eli Lilly and Company
- CGNXT3— Cognex Corporation
- ICLRT3— ICON Public Limited Company
- MEDPT3— Medpace Holdings, Inc.
- MLABT3— Mesa Laboratories, Inc.
- RPIDT3— Rapid Micro Biosystems, Inc.
- TMOT3— Thermo Fisher Scientific Inc.
- IQVT2· no notes yet
- 3696.HKT3· no notes yet
- AZTAT3· no notes yet
- DHRT3· no notes yet
- NOVTT3· no notes yet
- TWSTT3· no notes yet
- TXGT3· no notes yet